Megalotect (Human Cytomegalovirus Immunoglobulin)

Megalotect is used in clinical settings to prevent or treat cytomegalovirus (CMV) infection in high‑risk patient groups.

• Allogeneic hematopoietic stem cell transplant recipients: reduces incidence of CMV disease by providing passive antibodies.
• Solid organ transplant recipients: offers prophylaxis against CMV reactivation during the early post‑transplant period.
• Immunocompromised patients with active CMV infection: aids viral clearance when antiviral therapy alone is insufficient.

• Human Cytomegalovirus Immunoglobulin consists of purified IgG antibodies derived from donors with high titres against CMV. When administered intravenously, the antibodies bind to viral particles and infected cells, neutralizing viral entry and promoting opsonization. This passive immunity lowers viral replication and limits spread, supporting the host’s immune response until endogenous immunity can develop. The preparation also engages complement pathways, enhancing clearance of circulating virus.

Intravenous administration of CMV immunoglobulin may be associated with a range of adverse reactions, from mild to severe.

Common Side Effects

• Fever: transient elevation of body temperature shortly after infusion.
• Headache: mild to moderate headache occurring during or after the infusion.
• Nausea: occasional feeling of nausea or upset stomach.
• Chills: brief episodes of shaking or feeling cold.
• Fatigue: general tiredness reported by some patients.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction requiring immediate medical intervention.
• Acute hemolysis: rapid destruction of red blood cells leading to anemia.
• Thromboembolic events: formation of clots that may cause vascular occlusion.
• Renal impairment: sudden decrease in kidney function, especially in patients with pre‑existing disease.
• Aseptic meningitis: inflammation of the meninges without infection.

Before using Megalotect, clinicians should consider several precautionary measures to ensure patient safety.

• Assess patient history: screen for previous reactions to immunoglobulin products.
• Monitor vital signs: observe blood pressure, heart rate, and temperature during infusion.
• Adjust infusion rate: start slowly and increase gradually to reduce infusion‑related reactions.
• Evaluate renal function: check baseline creatinine in patients with kidney disease.
• Contraindications: avoid use in patients with known severe IgA deficiency and anti‑IgA antibodies.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

CMV immunoglobulin can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid)

• Live vaccines: concurrent administration may diminish vaccine efficacy or increase risk.
• High‑dose corticosteroids: may suppress the intended immune benefit of the immunoglobulin.

Moderate Interactions (Monitor Closely)

• Anticoagulants: immunoglobulin can affect coagulation parameters, requiring INR monitoring.
• ACE inhibitors: may increase risk of hypotension during infusion.
• Other intravenous immunoglobulins: combined use can raise viscosity and risk of renal complications.